CERO Quote, Financials, Valuation and Earnings

CEL-SCI Corp. has a net margin of -- compared to CERo Therapeutics Holdings, Inc.'s net margin of --. CERo Therapeutics Holdings, Inc.'s return on equity of -- beat CEL-SCI Corp.'s return on equity of -266.61%.

CERo Therapeutics Holdings, Inc. has a consensus price target of $30.00, signalling upside risk potential of 35194.12%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 657.58%. Given that CERo Therapeutics Holdings, Inc. has higher upside potential than CEL-SCI Corp., analysts believe CERo Therapeutics Holdings, Inc. is more attractive than CEL-SCI Corp..

CERo Therapeutics Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

CERo Therapeutics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CERo Therapeutics Holdings, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

CERo Therapeutics Holdings, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. CERo Therapeutics Holdings, Inc.'s net income of -$4.9M is higher than CEL-SCI Corp.'s net income of -$5.7M. Notably, CERo Therapeutics Holdings, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CERo Therapeutics Holdings, Inc. is -- versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma, Inc. has a net margin of -- compared to CERo Therapeutics Holdings, Inc.'s net margin of -953.4%. CERo Therapeutics Holdings, Inc.'s return on equity of -- beat IGC Pharma, Inc.'s return on equity of -94.42%.

CERo Therapeutics Holdings, Inc. has a consensus price target of $30.00, signalling upside risk potential of 35194.12%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.88 which suggests that it could grow by 1079.6%. Given that CERo Therapeutics Holdings, Inc. has higher upside potential than IGC Pharma, Inc., analysts believe CERo Therapeutics Holdings, Inc. is more attractive than IGC Pharma, Inc..

CERo Therapeutics Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.

CERo Therapeutics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CERo Therapeutics Holdings, Inc. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.

CERo Therapeutics Holdings, Inc. quarterly revenues are --, which are smaller than IGC Pharma, Inc. quarterly revenues of $191K. CERo Therapeutics Holdings, Inc.'s net income of -$4.9M is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, CERo Therapeutics Holdings, Inc.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CERo Therapeutics Holdings, Inc. is -- versus 24.65x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to CERo Therapeutics Holdings, Inc.'s net margin of -255.85%. CERo Therapeutics Holdings, Inc.'s return on equity of -- beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

CERo Therapeutics Holdings, Inc. has a consensus price target of $30.00, signalling upside risk potential of 35194.12%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -75.71%. Given that CERo Therapeutics Holdings, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe CERo Therapeutics Holdings, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

CERo Therapeutics Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

CERo Therapeutics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. CERo Therapeutics Holdings, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

CERo Therapeutics Holdings, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. CERo Therapeutics Holdings, Inc.'s net income of -$4.9M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, CERo Therapeutics Holdings, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 5.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CERo Therapeutics Holdings, Inc. is -- versus 6.80x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protalix Biotherapeutics, Inc. has a net margin of -- compared to CERo Therapeutics Holdings, Inc.'s net margin of 13.19%. CERo Therapeutics Holdings, Inc.'s return on equity of -- beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.

CERo Therapeutics Holdings, Inc. has a consensus price target of $30.00, signalling upside risk potential of 35194.12%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 525%. Given that CERo Therapeutics Holdings, Inc. has higher upside potential than Protalix Biotherapeutics, Inc., analysts believe CERo Therapeutics Holdings, Inc. is more attractive than Protalix Biotherapeutics, Inc..

CERo Therapeutics Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.

CERo Therapeutics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CERo Therapeutics Holdings, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

CERo Therapeutics Holdings, Inc. quarterly revenues are --, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. CERo Therapeutics Holdings, Inc.'s net income of -$4.9M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, CERo Therapeutics Holdings, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 25.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CERo Therapeutics Holdings, Inc. is -- versus 2.24x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.